European Association of Nuclear Medicine
Acronym: EANM
General Information
Identification Code: 348978437245-85
Website: [object Object]
Entity Form: not-for-profit association (gemeinnütziger Verein)
Registration Category: Non-governmental organisations, platforms and networks and similar
Registration Date: 2/7/2020
Last Update: 3/5/2024
EP Accredited Number: 1
Mission & Interests
Goals: The EANM is the largest organisation dedicated to nuclear medicine and multi-modality imaging and related subjects in Europe. It has become the umbrella organisation representing the specialty towards European and international institutions. Our vision is to optimise and advance science and education in the area of nuclear medicine for the benefit of public health and humanity within the concept of personalised healthcare. We aim at being the platform for dissemination and discussion of latest advances and improve the exchange of knowledge relating to the diagnosis, treatment and prevention of diseases through the use of unsealed radioactive substances and the properties of stable nuclides in medicine. To achieve this, we conduct scientific meetings, one annual congress, courses, webinars and publish policy and position papers as well as guidance documents. Collaboration with partner societies is a cornerstone of EANM's strategy.
Interests Represented: Does not represent commercial interests
Interests:
- Education and training
- Employment and social affairs
- Energy
- Public health
- Research and innovation
Levels of Interest:
- european
Activities
Main EU Legislative Proposals: Europe´s Beating Cancer Plan and all connected initiatives including the EU cancer mission ; SAMIRA Action Plan, and the related European Radioisotopes Valley Initiative ; Pharma strategy and the related European Pharmaceutical Package ; EU Non-Communicable Disease initiative ; Artificial Intelligence Regulation ; European Health Data Space ; Clinical Trials Directive and ACTEU ; European Health Technology Assessment ; Implementation of the BSS Directive ; Professional Qualification Recognition legislation ; Personalised medicine and precision oncology ; Workforce planning, education, mobility and safety ; European Commission Communication on Addressing Medicines Shortages in the EU ; Critical Medicines Alliance and Union List of Critical Medicines
Communication Activities: *Publication of the EANM Statement on the Union List of Critical Medicines "Rationale for inclusion of radioisotopes" (February 2024)
*Publication of EJNMMI Editorial: "The revision of the pharmaceutical legislation — it is time to act
for nuclear medicine in Europe" (November 2023)
*Publication of EANM-NMEU joint statement on the revision of the European Pharmaceutical Legislation: "Time to Act for Nuclear Medicine" (October 2023)
*Publication of EANM Statement on Animal Testing in the EU: "The potential adverse effect of a ban on biomedical research" (July 2023)
*Publication within the EJNMMI: "The QuADRANT study: current status and recommendations for improving uptake and implementation of clinical audit of medical radiological procedures in Europe—the nuclear medicine perspective" (May 2023)
*Quarterly publication of the EANM Policy Bulletin, a newsletter focusing on nuclear medicine and regulatory/policy topics
*Social Media Campaign on Animal Testing in the EU (Summer 2023)
*Social Media Campaign on the revision of the EU Pharmaceutical Legislation (Summer 2023)
*Organisation of 2 EU Policy Symposium during our annual Congress on Supply & Shortages of Radiopharmaceuticals and on Regulatory Hurdles for Radiopharmaceuticals (Septembre 2023)
* Publication of the EANM-EAHP joint statement on "the availability of radiopharmaceuticals in the context of the revision of the general pharmaceutical legislation" (December 2022)
* Publication of the EANM Overarching Narrative "Nuclear Medicine. What it is. Where it goes. What it needs. (June 2022)
* Publication of the "EANM position on the in-house preparation of radiopharmaceuticals" (December 2021)
* Publication of the "EANM Statement for a better inclusion of the particularities of Radiopharmaceuticals within the Review of Directive 2001/83EC on Pharmaceutical Legislation" (December 2021)
* Publication of the "EANM Statement: Posology for Radiopharmaceuticals: contradictory legal requirements between BSS Directive 2013/59/Euratom and EMA marketing authorisations schemes" (December 2021)
* Joint coalition statement: "Reducing bureaucracy in clinical trials: now is the time! as well as " as well as "Recommendations of the Coalition for Reducing Bureaucracy in Clinical Trials"
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: Schmalzhofgasse 26
Post Code: 1060
City: Vienna
Country: AUSTRIA
Phone: [object Object]
EU Office
Address: Schmalzhofgasse 26
Post Code: 1060
City: Vienna
Country: AUSTRIA
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: For 2023, financial year is not yet closed - annual closed accounts will be available around Mid-April 2024.
Membership Information
Members10 Percent: 6
Members25 Percent: 0
Members50 Percent: 0
Members75 Percent: 0
Members: 7
Members F T E: 1.600000023841858
Info Members: This number includes volunteers involved within the EANM Policy & Regulatory Affairs Council.
Structure
Structure Type: Structure
Is Member Of: 41 national member societies in the field of nuclear medicine:
https://www.eanm.org/about/organs/national-societies/
Additional "affiliated" member societies, not within the Council of Europe:
https://www.eanm.org/about/organs/affiliated-societies/
Industry partners:
https://www.eanm.org/advocacy/partnerships/financial-assessment/
Organisation Members: European Cancer Organisation - https://www.europeancancer.org/
European Alliance for Medical Radiation Protection Research (EURAMED) - https://www.euramed.eu/
European Institute for Biomedical Imaging Research (EIBIR) - https://www.eibir.org/
Coalition for Reducing Bureaucracy in Clinical Trials - https://bureaucracyincts.eu/